What's Going On With Vanda Pharmaceuticals Shares Today?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 27 2024
0mins
Should l Buy VNDA?
Source: Benzinga
- Vanda Pharmaceuticals Acquisition Proposal Withdrawn: Future Pak has withdrawn its proposal to purchase Vanda Pharmaceuticals Inc., citing lack of response and rejection of their final offer.
- Stock Performance: Vanda Pharmaceuticals' shares have declined over 9% in the past year, with investors being able to access the stock through Invesco NASDAQ Future Gen 200 ETF QQQS.
- Company's Response: Vanda Pharmaceuticals stated that takeover proposals from Future Pak and Cycle Group undervalued the company, leading to the rejection of these offers by the Board.
- FDA Approval: In April, the FDA approved Vanda Pharmaceuticals' Fanapt tablets for the treatment of manic or mixed episodes associated with bipolar I disorder in adults.
- Current Stock Price: As of the latest check, VNDA shares are trading lower by 1.92% at $5.865.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VNDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VNDA
Wall Street analysts forecast VNDA stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 7.270
Low
7.50
Averages
13.63
High
22.00
Current: 7.270
Low
7.50
Averages
13.63
High
22.00
About VNDA
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company, which is focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vanda Pharmaceuticals Urges FDA to Withdraw Legislative Proposal
- Proposal Details: The FDA's FY 2027 Congressional Budget proposal seeks to eliminate the 180-day review requirement for new drug applications (NDAs), extending review timelines to 10-12 months, which could delay patient access to new medications.
- Vanda's Position: Vanda Pharmaceuticals argues that this change would exacerbate review delays, reduce transparency, and increase risks for small innovators, with CEO Mihael H. Polymeropoulos emphasizing that the FDA should comply with existing laws rather than seek to amend them to allow for slower reviews.
- Legal Context: Vanda highlights that federal courts have ruled the FDA's practice of exceeding the 180-day timeline as unlawful, and the agency currently takes up to two months just to decide whether to file an application, raising concerns about the proposal's implications.
- Industry Impact: The proposal could lead to longer wait times for patients to access new drugs and greater uncertainty for biotech innovators, prompting Vanda to urge FDA Commissioner Dr. Marty Makary to withdraw the provision and call on Congress to reject it.
See More
Healthcare Stocks Mixed as NYSE Health Care Index Edges Up 0.1%
- Mixed Market Performance: Late Thursday afternoon, healthcare stocks showed mixed results, with the NYSE Health Care Index rising by 0.1%, indicating a cautious market sentiment towards the healthcare sector amid economic uncertainties.
- Investor Sentiment Fluctuations: While the overall index saw a slight increase, individual healthcare stocks exhibited varied performances, influenced by company earnings reports and market dynamics, highlighting the volatility and uncertainty in investor sentiment.
- Uncertain Industry Outlook: The future of the healthcare industry faces challenges, particularly in light of changing policies and economic conditions, prompting investors to closely monitor potential impacts from regulatory changes on the sector.
- Long-Term Trends to Watch: Despite the mixed short-term performance of healthcare stocks, the sector is still viewed as having growth potential in the long run, driven by an aging population and increasing health demands.
See More
Vanda Pharmaceuticals Opposes FDA Proposal to Extend Drug Review Timelines
- Legislative Impact: The FDA's proposal in the FY 2027 budget seeks to eliminate the 180-day review requirement for new drug applications (NDAs), extending review times to 10 to 12 months, which could lead to longer waits for patients needing medications.
- Review Process Changes: The proposal replaces the formal evidentiary hearing process with a weaker internal appeal, potentially reducing transparency and increasing financial risks and uncertainties for small innovative companies like Vanda.
- Legal Compliance Issues: Vanda's CEO Polymeropoulos highlighted that the FDA's current practices have been ruled illegal by federal courts, yet the proposal aims to legalize these delays, indicating a disregard for the law.
- Call to Withdraw Proposal: Vanda urges FDA Commissioner Makary to withdraw the proposal and calls on Congress to reject legislation that could harm patient interests and stifle innovation.
See More
Vanda Pharmaceuticals Opposes FDA Proposal to Extend Drug Review Timelines
- Legislative Impact: The FDA's FY 2027 budget proposal seeks to eliminate the 180-day statutory requirement for reviewing new drug applications, which could extend review times to 10-12 months, increasing patient wait times for essential medications.
- Decreased Transparency: The proposal replaces the formal evidentiary hearing process with a weaker internal appeal, potentially diminishing patient transparency and trust in the approval process while entrenching bureaucratic inertia over innovation.
- Legal Compliance Issues: Vanda's CEO Polymeropoulos highlighted that the FDA's current practices have been ruled illegal by federal courts, and this proposal aims to legalize such delays, posing greater financial risks and uncertainties for small innovators.
- Call to Withdraw Proposal: Vanda urges FDA Commissioner Makary to withdraw the proposal and calls on Congress to reject it, emphasizing that it contradicts the goal of improving efficiency and could hinder patient access to necessary drugs.
See More
VANDA PHARMACEUTICALS INC - PLAN AIMS TO REMOVE FDA'S 180-DAY NDA REVIEW OBLIGATION
- Proposal Overview: Vanda Pharmaceuticals has proposed to eliminate the FDA's 180-day new drug application (NDA) review requirement.
- Impact on Drug Approval: This change could streamline the drug approval process, potentially allowing for faster access to new medications.
See More
Vanda Pharmaceuticals Initiates Thetis Trial for NEREUS in GLP-1 Therapy
- Trial Initiation: Vanda Pharmaceuticals has announced the initiation of the Thetis clinical trial to evaluate NEREUS™ (tradipitant) for preventing vomiting in patients undergoing GLP-1 receptor agonist therapy, addressing a significant barrier to treatment adherence due to nausea and vomiting.
- Efficacy Validation: In a prior Phase 2 study, only 29.3% of participants treated with tradipitant experienced vomiting compared to 58.6% in the placebo group (p=0.0016), highlighting its potential to mitigate GLP-1 related side effects and improve patient compliance.
- Multicenter Design: The Thetis study is designed as a multicenter, randomized, double-blind, placebo-controlled trial, primarily assessing the proportion of patients free from vomiting episodes during high-dose GLP-1 treatment, which is expected to provide critical data for future drug applications.
- Market Potential: With the increasing use of GLP-1 receptor agonists in diabetes and obesity treatment, the successful development of NEREUS™ could enhance patient quality of life and further strengthen Vanda's competitive position in the biopharmaceutical market.
See More
Vanda Pharmaceuticals Urges FDA to Withdraw Legislative Proposal
- Proposal Details: The FDA's FY 2027 Congressional Budget proposal seeks to eliminate the 180-day review requirement for new drug applications (NDAs), extending review timelines to 10-12 months, which could delay patient access to new medications.
- Vanda's Position: Vanda Pharmaceuticals argues that this change would exacerbate review delays, reduce transparency, and increase risks for small innovators, with CEO Mihael H. Polymeropoulos emphasizing that the FDA should comply with existing laws rather than seek to amend them to allow for slower reviews.
- Legal Context: Vanda highlights that federal courts have ruled the FDA's practice of exceeding the 180-day timeline as unlawful, and the agency currently takes up to two months just to decide whether to file an application, raising concerns about the proposal's implications.
- Industry Impact: The proposal could lead to longer wait times for patients to access new drugs and greater uncertainty for biotech innovators, prompting Vanda to urge FDA Commissioner Dr. Marty Makary to withdraw the provision and call on Congress to reject it.
See More
Healthcare Stocks Mixed as NYSE Health Care Index Edges Up 0.1%
- Mixed Market Performance: Late Thursday afternoon, healthcare stocks showed mixed results, with the NYSE Health Care Index rising by 0.1%, indicating a cautious market sentiment towards the healthcare sector amid economic uncertainties.
- Investor Sentiment Fluctuations: While the overall index saw a slight increase, individual healthcare stocks exhibited varied performances, influenced by company earnings reports and market dynamics, highlighting the volatility and uncertainty in investor sentiment.
- Uncertain Industry Outlook: The future of the healthcare industry faces challenges, particularly in light of changing policies and economic conditions, prompting investors to closely monitor potential impacts from regulatory changes on the sector.
- Long-Term Trends to Watch: Despite the mixed short-term performance of healthcare stocks, the sector is still viewed as having growth potential in the long run, driven by an aging population and increasing health demands.
See More
Vanda Pharmaceuticals Opposes FDA Proposal to Extend Drug Review Timelines
- Legislative Impact: The FDA's proposal in the FY 2027 budget seeks to eliminate the 180-day review requirement for new drug applications (NDAs), extending review times to 10 to 12 months, which could lead to longer waits for patients needing medications.
- Review Process Changes: The proposal replaces the formal evidentiary hearing process with a weaker internal appeal, potentially reducing transparency and increasing financial risks and uncertainties for small innovative companies like Vanda.
- Legal Compliance Issues: Vanda's CEO Polymeropoulos highlighted that the FDA's current practices have been ruled illegal by federal courts, yet the proposal aims to legalize these delays, indicating a disregard for the law.
- Call to Withdraw Proposal: Vanda urges FDA Commissioner Makary to withdraw the proposal and calls on Congress to reject legislation that could harm patient interests and stifle innovation.
See More
Vanda Pharmaceuticals Opposes FDA Proposal to Extend Drug Review Timelines
- Legislative Impact: The FDA's FY 2027 budget proposal seeks to eliminate the 180-day statutory requirement for reviewing new drug applications, which could extend review times to 10-12 months, increasing patient wait times for essential medications.
- Decreased Transparency: The proposal replaces the formal evidentiary hearing process with a weaker internal appeal, potentially diminishing patient transparency and trust in the approval process while entrenching bureaucratic inertia over innovation.
- Legal Compliance Issues: Vanda's CEO Polymeropoulos highlighted that the FDA's current practices have been ruled illegal by federal courts, and this proposal aims to legalize such delays, posing greater financial risks and uncertainties for small innovators.
- Call to Withdraw Proposal: Vanda urges FDA Commissioner Makary to withdraw the proposal and calls on Congress to reject it, emphasizing that it contradicts the goal of improving efficiency and could hinder patient access to necessary drugs.
See More
VANDA PHARMACEUTICALS INC - PLAN AIMS TO REMOVE FDA'S 180-DAY NDA REVIEW OBLIGATION
- Proposal Overview: Vanda Pharmaceuticals has proposed to eliminate the FDA's 180-day new drug application (NDA) review requirement.
- Impact on Drug Approval: This change could streamline the drug approval process, potentially allowing for faster access to new medications.
See More
Vanda Pharmaceuticals Initiates Thetis Trial for NEREUS in GLP-1 Therapy
- Trial Initiation: Vanda Pharmaceuticals has announced the initiation of the Thetis clinical trial to evaluate NEREUS™ (tradipitant) for preventing vomiting in patients undergoing GLP-1 receptor agonist therapy, addressing a significant barrier to treatment adherence due to nausea and vomiting.
- Efficacy Validation: In a prior Phase 2 study, only 29.3% of participants treated with tradipitant experienced vomiting compared to 58.6% in the placebo group (p=0.0016), highlighting its potential to mitigate GLP-1 related side effects and improve patient compliance.
- Multicenter Design: The Thetis study is designed as a multicenter, randomized, double-blind, placebo-controlled trial, primarily assessing the proportion of patients free from vomiting episodes during high-dose GLP-1 treatment, which is expected to provide critical data for future drug applications.
- Market Potential: With the increasing use of GLP-1 receptor agonists in diabetes and obesity treatment, the successful development of NEREUS™ could enhance patient quality of life and further strengthen Vanda's competitive position in the biopharmaceutical market.
See More
